Pharmaxis Ltd News

Pharmaxis Ltd Director Increases Stock Options

TipRanksNov 28 22:07 ET

Pharmaxis Ltd: A Powerhouse of Pharmaceutical Expertise

TipRanksNov 27 18:09 ET

Pharmaxis Ltd Calls for Key Shareholder Vote

TipRanksAug 19 22:38 ET

Pharmaxis Advances Cancer Drug in German Trials

TipRanksAug 7 21:17 ET

Pharmaxis Shareholding Shifts With Platinum Moves

TipRanksAug 7 03:36 ET

Pharmaxis Ltd Announces Upcoming Equity Raise

TipRanksJul 29 23:38 ET

Pharmaxis Ltd's Aspirations Amidst Uncertainties

TipRanksApr 30 03:28 ET

Pharmaxis Ltd Advances Clinical Trials, Boosts Savings

TipRanksApr 29 21:08 ET

Pharmaxis Ltd Announces Major Shareholder Changes

TipRanksApr 15 02:37 ET

Syntara Receives AU$5.2 Million R&D Tax Rebate

MT NewswiresDec 5, 2023 02:42 ET

Pharmaxis Doses First Patient in Phase Two Sleep Trial

MT NewswiresNov 10, 2023 04:41 ET

Pharmaxis Sells Mannitol Business; Shares Fall 3%

MT NewswiresOct 18, 2023 22:11 ET

Pharmaxis Target Price Raised 31% to A$0.17/Share by Morgans>PXS.AU

Dow JonesOct 8, 2023 18:00 ET

Pharmaxis to Change Name Amid Restructure, Appoints Chair

MT NewswiresOct 3, 2023 05:13 ET

Pharmaxis to Be Renamed Syntara and Will Primarily Focus on Clinical Development

Dow JonesOct 2, 2023 18:43 ET

Pharmaxis Chair Malcolm McComas Retires

Dow JonesOct 2, 2023 18:42 ET

Pharmaxis to Sell Mannitol Respiratory Business to Arna Pharma

Dow JonesOct 2, 2023 18:41 ET

Pharmaxis Plans 'Major' Restructuring

Dow JonesOct 2, 2023 18:40 ET

Australian Bourse Halts Trading in Pharmaxis' Securities

MT NewswiresOct 2, 2023 04:55 ET

Pharmaxis Target Price Cut 46% to A$0.13/Share by Morgans>PXS.AU

Dow JonesAug 22, 2023 19:55 ET